CL2007003826A1 - Compuestos derivados de n-(amino-(hetero)aril)-1h-pirrolopiridin-2-carboxamidas, antagonistas de receptores tipo trpv1; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como trastornos gastrointestinales, trastornos respiratorios, psoriasis y depresion. - Google Patents

Compuestos derivados de n-(amino-(hetero)aril)-1h-pirrolopiridin-2-carboxamidas, antagonistas de receptores tipo trpv1; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como trastornos gastrointestinales, trastornos respiratorios, psoriasis y depresion.

Info

Publication number
CL2007003826A1
CL2007003826A1 CL2007003826A CL2007003826A CL2007003826A1 CL 2007003826 A1 CL2007003826 A1 CL 2007003826A1 CL 2007003826 A CL2007003826 A CL 2007003826A CL 2007003826 A CL2007003826 A CL 2007003826A CL 2007003826 A1 CL2007003826 A1 CL 2007003826A1
Authority
CL
Chile
Prior art keywords
psoriasis
depression
diseases
pharmaceutical composition
treatment
Prior art date
Application number
CL2007003826A
Other languages
English (en)
Inventor
Laurent Dubois
Yannick Evanno
Andre Malanda
Catherine Gille
David Machnik
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CL2007003826A1 publication Critical patent/CL2007003826A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)

Abstract

LA INVENCIÓN SE REFIERE A COMPUESTOS DE LA FORMULA GENERAL ( I):<br /> EN LA QUE X, Y, Z, Z1, Z2, Z3, Z4, Y N SON COMO SE DEFINEN EN LA MEMORIA DESCRIPTIVA Y PLIEGO; PROCEDIMIENTO DE PREPARACIÓN : COMPOSICIÓN FARMACÉUTICA Y USO EN EL TRATAMIENTO DE ENFERMEDADES TA LES COMO TRASTORNOS GASTROINTESTINALES, TRASTORNOS RESPIRATORIOS, PSORIASIS Y DEPRESIÓN.  
CL2007003826A 2006-12-26 2007-12-26 Compuestos derivados de n-(amino-(hetero)aril)-1h-pirrolopiridin-2-carboxamidas, antagonistas de receptores tipo trpv1; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como trastornos gastrointestinales, trastornos respiratorios, psoriasis y depresion. CL2007003826A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0611353A FR2910473B1 (fr) 2006-12-26 2006-12-26 Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.

Publications (1)

Publication Number Publication Date
CL2007003826A1 true CL2007003826A1 (es) 2009-01-23

Family

ID=38234895

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2007003826A CL2007003826A1 (es) 2006-12-26 2007-12-26 Compuestos derivados de n-(amino-(hetero)aril)-1h-pirrolopiridin-2-carboxamidas, antagonistas de receptores tipo trpv1; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como trastornos gastrointestinales, trastornos respiratorios, psoriasis y depresion.

Country Status (11)

Country Link
US (3) US8153650B2 (es)
EP (1) EP2125811B1 (es)
JP (1) JP5284274B2 (es)
AR (1) AR064524A1 (es)
CL (1) CL2007003826A1 (es)
FR (1) FR2910473B1 (es)
PA (1) PA8764301A1 (es)
PE (1) PE20081549A1 (es)
TW (1) TW200835486A (es)
UY (1) UY30842A1 (es)
WO (1) WO2008093024A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2910473B1 (fr) * 2006-12-26 2009-02-13 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
FR2926556B1 (fr) * 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
FR2926554B1 (fr) * 2008-01-22 2010-03-12 Sanofi Aventis Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
FR2926553B1 (fr) * 2008-01-23 2010-02-19 Sanofi Aventis Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique
KR20190007106A (ko) 2011-12-21 2019-01-21 노비라 테라퓨틱스, 인코포레이티드 B형 간염의 항바이러스성 제제
NZ743463A (en) 2012-08-28 2019-09-27 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
DK2961732T3 (en) 2013-02-28 2017-07-10 Janssen Sciences Ireland Uc SULFAMOYLARYLAMIDS AND USE THEREOF AS MEDICINES TO TREAT HEPATITIS B
WO2014161888A1 (en) 2013-04-03 2014-10-09 Janssen R&D Ireland N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
LT2997019T (lt) 2013-05-17 2018-11-26 Janssen Sciences Ireland Uc Sulfamoiltiofenamido dariniai ir jų panaudojimas kaip vaistų hepatito b gydymui
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
LT3024819T (lt) 2013-07-25 2018-06-11 Janssen Sciences Ireland Uc Pirolamido dariniai, turintys glioksamido pakaitų, ir jų panaudojimas kaip vaistų hepatito b gydymui
JP6452119B2 (ja) 2013-10-23 2019-01-16 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カルボキサミド誘導体およびｂ型肝炎の処置のための医薬品としてのその使用
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
EP3102225B1 (en) 2014-02-05 2020-03-25 Novira Therapeutics Inc. Combination therapy for treatment of hbv infections
CN110483484A (zh) 2014-02-06 2019-11-22 爱尔兰詹森科学公司 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
WO2016149581A1 (en) 2015-03-19 2016-09-22 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
HUE057041T2 (hu) 2015-07-06 2022-04-28 Alkermes Inc Hiszton deacetiláz hetero-halogén gátlói
TW201718496A (zh) 2015-09-29 2017-06-01 諾維拉治療公司 B型肝炎抗病毒劑之晶型
AU2017248828A1 (en) 2016-04-15 2018-11-01 Janssen Sciences Ireland Uc Combinations and methods comprising a capsid assembly inhibitor
PL3570834T3 (pl) 2017-01-11 2022-05-23 Alkermes, Inc. Bicykliczne inhibitory deacetylazy histonowej
RS63343B1 (sr) 2017-08-07 2022-07-29 Alkermes Inc Biciklični inhibitori histonske deacetilaze
CN111867582A (zh) 2018-03-14 2020-10-30 爱尔兰詹森科学公司 衣壳组装调节剂给药方案
MA55020A (fr) 2019-02-22 2021-12-29 Janssen Sciences Ireland Unlimited Co Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
JP2022532526A (ja) 2019-05-06 2022-07-15 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Ｈｂｖ感染又はｈｂｖ誘導性疾患の処置において有用なアミド誘導体

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL248308A (es) * 1958-09-30
US6630496B1 (en) * 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
US6436965B1 (en) * 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
BR0116113A (pt) 2000-12-12 2004-08-03 Neurogen Corp Espiro[isobenzofuran-1,4'-piperidin]-3-onas e 3h-espiroisoben-zofuran-1,4'-piperidinas
DE10147672A1 (de) * 2001-09-27 2003-04-10 Bayer Ag Substituierte 2,5-Diamidoindole und ihre Verwendung
TW200403223A (en) 2002-02-15 2004-03-01 Glaxo Group Ltd Novel compounds
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
JP2004091480A (ja) * 2002-07-11 2004-03-25 Takeda Chem Ind Ltd ピロロピリジン誘導体およびその用途
AU2003281044A1 (en) * 2002-07-11 2004-02-02 Takeda Pharmaceutical Company Limited Pyrrolopyridine derivative and use thereof
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
EP1578418A2 (en) * 2002-12-20 2005-09-28 Bayer HealthCare AG Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
JP2006515334A (ja) 2003-01-16 2006-05-25 エスビー ファームコ プエルト リコ インコーポレーテッド ＣＲＦ受容体アンタゴニストとしてのヘテロアリール置換ピロロ［２，３−ｂ］ピリジン誘導体
JP4909068B2 (ja) 2003-02-14 2012-04-04 グラクソ グループ リミテッド カルボキサミド誘導体
AR045979A1 (es) 2003-04-28 2005-11-23 Astrazeneca Ab Amidas heterociclicas
WO2004108133A2 (en) 2003-06-05 2004-12-16 Vertex Pharmaceuticals Incorporated Modulators of vr1 receptor
WO2004110986A1 (ja) 2003-06-12 2004-12-23 Astellas Pharma Inc. ベンズアミド誘導体又はその塩
JP2007505888A (ja) 2003-09-22 2007-03-15 ファイザー インコーポレイテッド オキシトシン拮抗薬としての置換トリアゾール誘導体
WO2005035526A1 (en) 2003-10-09 2005-04-21 Argenta Discovery Ltd. Bicyclic compounds and their therapeutic use
CA2542494A1 (en) * 2003-10-15 2005-05-06 Bayer Healthcare Ag Tetrahydro-naphthalene and urea derivatives
US7544803B2 (en) * 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
FR2874015B1 (fr) * 2004-08-05 2006-09-15 Sanofi Synthelabo Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
WO2006040522A1 (en) 2004-10-12 2006-04-20 Astrazeneca Ab Quinoline derivatives
FR2888848B1 (fr) 2005-07-22 2007-09-28 Sanofi Aventis Sa Derives de n-(arylalkyl)-1h-pyrrrolopyridine-2-carboxamides, leur preparation et leur application en therapeutique
JP5076091B2 (ja) * 2005-11-28 2012-11-21 マドリガル・ファーマシューティカルズ・インコーポレーテッド ジアシルグリセロールアシルトランスフェラーゼ（ｄｇａｔ）のインヒビター
FR2910473B1 (fr) 2006-12-26 2009-02-13 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
NZ584279A (en) * 2007-09-19 2011-11-25 4Sc Ag Novel tetrahydrofusedpyridines as histone deacetylase inhibitors

Also Published As

Publication number Publication date
TW200835486A (en) 2008-09-01
US8153650B2 (en) 2012-04-10
US20100041634A1 (en) 2010-02-18
EP2125811A2 (fr) 2009-12-02
WO2008093024A2 (fr) 2008-08-07
FR2910473A1 (fr) 2008-06-27
JP5284274B2 (ja) 2013-09-11
US8716272B2 (en) 2014-05-06
US20120142669A1 (en) 2012-06-07
EP2125811B1 (fr) 2013-05-29
WO2008093024A3 (fr) 2008-10-02
JP2010514742A (ja) 2010-05-06
AR064524A1 (es) 2009-04-08
PE20081549A1 (es) 2008-12-14
US20120142670A1 (en) 2012-06-07
FR2910473B1 (fr) 2009-02-13
PA8764301A1 (es) 2008-11-19
US8716273B2 (en) 2014-05-06
UY30842A1 (es) 2008-07-31

Similar Documents

Publication Publication Date Title
CL2007003826A1 (es) Compuestos derivados de n-(amino-(hetero)aril)-1h-pirrolopiridin-2-carboxamidas, antagonistas de receptores tipo trpv1; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como trastornos gastrointestinales, trastornos respiratorios, psoriasis y depresion.
CY1115175T1 (el) Ενωσεις 9-υποκατεστημενης-8-οξο-αδενινης ως ρυθμιστες υποδοχεων τυπου toll (tlr7)
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
UY32996A (es) Antagonistas del receptor crth2 basados en indol
EA200970341A1 (ru) Пиразолиновые соединения в качестве антагонистов минералокортикоидных рецепторов
EA201201343A1 (ru) Производные 4-аминопиримидина и их действующее вещество как антагонисты аденозинового рецептора а
EA201001724A1 (ru) Производные изоксазола и их применение в качестве потенциирующих средств для метаботропных глутаматных рецепторов
UY31254A1 (es) Derivados sutituidos de n4-(5-metil-1h-pirazol-3-il)- 1,3,5-triazina-2,4-diamina, sus enantiómeros, sales farmacéuticamente aceptables de los mismos, composiciones, procesos de preparación y aplicaciones
EA201591204A3 (ru) Новые хиральные n-ацил-5,6,7,(8-замещенные)-тетрагидро-[1,2,4]триазоло[4,3-а]пиразины как селективные антагонисты рецептора nk-3, фармацевтическая композиция, способы применения при нарушениях, опосредованных nk-3 рецепторами, и их хиральный синтез
CY1112255T1 (el) Ενωσεις οι οποιες περιεχουν γουανιδινη που ειναι χρησιμες ως ανταγωνιστες του μουσκαρινικου υποδοχεα
MX2010003001A (es) Derivados de quinolina como antagonistas del receptor de la 5-hidroxitriptamina 5a.
CY1118314T1 (el) Συνδυασμοι αγωνιστων υποδοχεα σεροτονινης για την αγωγη κινητικων διαταραχων
CY1113759T1 (el) Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
MX2010008713A (es) Derivados de 5,6-bisaril-2-piridina-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de la urotensina ii.
NZ605431A (en) D2 antagonists, methods of synthesis and methods of use
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
EA200800421A1 (ru) Соединения
CY1113820T1 (el) Παραγωγα 4-αλκοξυπυριδαζινης ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу
ECSP10010606A (es) Derivados de quinuclidina como antagonistas de receptores muscarinicos m3
MX2011006821A (es) Derivados de imidazol fusionados como antagonistas de trpv3.
EA201000675A1 (ru) Производные хромана как модуляторы trpv3
CO6300937A2 (es) Derivados de 3-carboxipropil-aminotetralina y compuestos relacionados como antagonistas de receptores opioides mu
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
NI201100015A (es) Compuestos novedosos activos como antagonistas de receptor muscarínico.